Business Context and Reporting Period
This Form 10-Q covers AmerisourceBergen Corporation (note: the input metadata lists "Cencora, Inc.", but the filing text identifies the registrant as AmerisourceBergen Corporation) for the quarterly period ended March 31, 2004. The Company is a leading national pharmaceutical services provider organized into two reportable segments: Pharmaceutical Distribution and PharMerica. The report includes unaudited consolidated financial statements and management discussion regarding the first half of fiscal year 2004.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2004 | Six Months Ended Mar 31, 2004 |
|---|---|---|
| Total Revenue | $13.36 billion | $26.72 billion |
| Operating Revenue (excl. bulk) | $12.34 billion | $24.61 billion |
| Gross Profit | $582.4 million | $1.11 billion |
| Operating Income | $258.3 million | $468.8 million |
| Net Income | $142.2 million | $250.6 million |
| Diluted EPS | $1.23 | $2.17 |
| Cash and Equivalents (Mar 31, 2004) | $663.8 million | |
| Total Debt (Mar 31, 2004) | $1.75 billion | |
| Operating Cash Flow (6 months) | $22.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 10% year-over-year for both the quarter and six-month periods, driven primarily by the Pharmaceutical Distribution segment. Bulk deliveries increased 7% in the quarter but decreased 7% over six months due to business model shifts.
- Profitability: Net income rose 22% for the quarter and 20% for the six-month period compared to the prior year. Diluted EPS increased 19% and 16%, respectively.
- Margins: Gross profit margins declined slightly (4.72% vs. 5.18% for the quarter) due to competitive pricing pressures and customer mix changes. However, operating expense ratios improved significantly (2.63% vs. 3.07% for the quarter) due to merger integration efficiencies and a $17.5 million reduction in bad debt allowance.
- Cash Flow: Operating cash flow turned positive ($22.0 million) for the six months ended March 31, 2004, a significant improvement from a cash use of $615.3 million in the prior-year period. This was driven by a $128.9 million decrease in merchandise inventories and improved working capital management.
- Debt: Interest expense decreased 20% for the quarter and 14% for the six-month period due to reduced average borrowings.
Guidance, Outlook, and Risks
- Guidance Revision: The Company reduced its forecasted diluted EPS range for fiscal 2004 by $0.40 per share following the cessation of servicing the U.S. Department of Veterans Affairs (VA) in May 2004. The VA accounted for 8% of operating revenue in the first half of 2004.
- Customer Risks: The Company faces potential loss of business from AdvancePCS (approx. 4-5% of revenue) following its acquisition by Caremark, a competitor's customer. A six-month contract extension was secured through September 2004.
- Redemptions and Gains: The Company plans to redeem $300 million of Trust Preferred Securities and $8.4 million of subordinated debentures in the June 2004 quarter, incurring an estimated $24 million loss. Conversely, a $38.0 million gain is expected from an antitrust litigation settlement in the same quarter.
- Integration: The Company continues facility consolidation, aiming for a network of 30 facilities. It expects to close four additional facilities by October 2004.
- Legal Matters: Pending matters include a stockholder derivative lawsuit, a DOJ investigation regarding a former customer, and various commercial disputes (e.g., Bracco Diagnostics, Petters Company). Management does not believe these will have a material adverse effect.
Investor Verification Checklist
- VA Contract Impact: Verify the long-term revenue impact of losing the Department of Veterans Affairs contract and the success of the AdvancePCS contract extension.
- Margin Pressure: Monitor gross margin trends in the Pharmaceutical Distribution segment given competitive pricing and the shift toward institutional customers.
- Debt Redemption Costs: Confirm the timing and financial impact of the $24 million loss associated with the May 2004 debt redemptions.
- Antitrust Settlement: Track the realization of the expected $38.0 million gain from the supplier antitrust settlement in the second quarter.
- Working Capital: Assess the sustainability of the improved operating cash flow driven by inventory management agreements and reduced inventory levels.